Fenofibrate pharmaceutical composition having high...

Details Fenofibrate pharmaceutical composition having high... Fenofibrate pharmaceutical composition having high...

2006-05-09

2006-05-09

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S490000, C424S451000, C424S452000, C424S464000, C424S465000

Reexamination Certificate

active

07041319

ABSTRACT:
The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.

REFERENCES:
patent: 2953497 (1960-09-01), Press
patent: 4412986 (1983-11-01), Kawata et al.
patent: 4524060 (1985-06-01), Mughal et al.
patent: 4629624 (1986-12-01), Grouiller et al.
patent: 4684516 (1987-08-01), Bhutani
patent: 4721709 (1988-01-01), Seth et al.
patent: 4800079 (1989-01-01), Boyer
patent: 4895726 (1990-01-01), Curtet et al.
patent: 4992277 (1991-02-01), Sangekar et al.
patent: 5073379 (1991-12-01), Klimesch et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5545628 (1996-08-01), Deboeck et al.
patent: 5633015 (1997-05-01), Gilis et al.
patent: 5776495 (1998-07-01), Duclos et al.
patent: 6027747 (2000-02-01), Terracol et al.
patent: 6042847 (2000-03-01), Kerc et al.
patent: 6180138 (2001-01-01), Engh et al.
patent: 2001/0006655 (2001-07-01), Chen et al.
patent: 2002/0009496 (2002-01-01), Stamm et al.
patent: 2002/0114839 (2002-08-01), Stamm et al.
patent: 2002/0168413 (2002-11-01), Stamm et al.
patent: 2003/0104051 (2003-06-01), Stamm et al.
patent: 2003/0104060 (2003-06-01), Stamm et al.
patent: 2004/0057997 (2004-03-01), Stamm et al.
patent: 2004/0057998 (2004-03-01), Stamm et al.
patent: 2004/0057999 (2004-03-01), Stamm et al.
patent: 2004/0058004 (2004-03-01), Stamm et al.
patent: 2004/0058005 (2004-03-01), Stamm et al.
patent: 2004/0092597 (2004-05-01), Stamm et al.
patent: 960670 (1975-01-01), None
patent: 2142848 (1994-03-01), None
patent: 2219475 (2002-07-01), None
patent: 2372576 (2004-02-01), None
patent: 0 330 532 (1989-08-01), None
patent: 0 519 144 (1992-12-01), None
patent: 0 761 208 (1997-03-01), None
patent: 0 793 958 (1997-09-01), None
patent: 0 256 933 (1998-02-01), None
patent: 0 952 829 (2003-03-01), None
patent: WO 82/01649 (1982-05-01), None
patent: WO 96/01621 (1996-01-01), None
patent: WO 97/12581 (1997-04-01), None
patent: WO 98/31360 (1998-07-01), None
patent: WO 98/31361 (1998-07-01), None
Complaint, US District Court for the District of Delaware, Civil Action No. 04-350,Reliang Pharmaceuticalsv.Abbott Laboratories et al(Jun. 1, 2004).
Opposition to EP 0 952 829 (Dec. 11, 2003) (English language translation).
Opposition to EP 0 952 829 (Dec. 11, 2003) (original French language document).
Handbook of Pharmaceutical Excipients, Second Edition, pp. 392-399 (1994).
Opposition to EP 0 952 829 (Dec. 11, 2003) (English language translation).
Laboratoires Fournier Lab Notebook No. 1 (Feb. 18, 1997 to May 15, 1997).
Laboratoires Fournier Lab Notebook No. 2 (May 16, 1997 to Jul. 30, 1997).
Temeljotov et al, Acta Pharm., 46:131-136 (1996).
“Second Amended Answer, Affirmative Defenses, and Counterclaims” filed by Teva on Jul. 29, 2005 in Abbott Laboratories et al v. Teva Pharmaceticals USA, Inc., De, CA No. 02-1512.
“First Amended Counterclaims” filed by Impax on Sep. 23, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Amended Complaint” filed by CVS Pharmacy et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Amended Complaint” filed by Walgreen Co. et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Complaint”filed by Painters'District Council No. 30 et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“First Amended Complaint” filed by Louisiana Wholesale Drug Co. et al, on Oct. 3, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Defendant'Responses to Plaintiffs Interrogatories” filed by Impax on Aug. 6, 2003 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Amended Answer”filed by Impax on Jan. 4, 2005 in Abbott Laboratories et al v. Impax Labortories, Inc., Delaware, CA No. 03-120-KAJ.
“Reply Memorandum” filed by Impax on Feb. 25, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Memorandum Opinion”by District Judge Jordan dated May 6, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Opening Brief in Support of Motion for Summary Judgement” by Teva filed on Dec. 23, 2004 in Abbott Laboratories et al v. Teva Pharmaceutial USA, Inc., Delaware, CA No. 02-1512.
“Opening Brief in Support of Motion for Summary Judgement” by Teva filed on Dec. 10, 2004 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512.
“Memorandum Opinion”by District Judge Jordan dated May 6, 2005 in Abbott Laboratories et al v. Teva Pharmaceutial USA, Inc., Delaware, CA No. 02-1512.
Opposition to European Patent No. 1 273 293 filed on Sep. 2, 2005 by Ethypharm (French Language Document).
Opposition to Israel Patent No. 130790 filed May 4, 2005 by Teva; and Remarks in Response to Opposition filed on Sep. 23, 2005. (English Language Translations).
Munoz et al, Atherosclerosis, 110(Suppl.):S45-S48 (1994).
Pharmaceutical Pelletization Technology, Marcel Dekker, Inc., vol. 37, pp. 1-13; 160-161; and 234-235 (1989).
Modern Pharmacetics, Third Edition, Marcel Dekker, Inc., pp. 131-133 and 335-336 (1996).
Pharmaceutical Dosage Forms, Tablets, Second Edition, Marcel Dekker, Inc., pp. 5-28; 88-107; 133; 142; 160-165; and 260-267 (1989).
Shepherd, Atherosclerosis, 110(Suppl.):S55-S63 (1994).
Adkins et al, Drugs, 54(4):615-633 (Oct. 1997).
Letter from Teva/Novopharm to Foumler Pharma Inc. regarding Invalidity and Ambiguity of Canadian Patent Nos. 2,219,475 and 2,372,576 (pages 1-15) (Sep. 19, 2005).

Affiliated with

Also associated with

Rating

Fenofibrate pharmaceutical composition having high... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fenofibrate pharmaceutical composition having high..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fenofibrate pharmaceutical composition having high... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3599396